EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Design and expression of a chimeric recombinant antigen (SsIR-Ss1a) for the serodiagnosis of human strongyloidiasis: Evaluation of performance, sensitivity, and specificity

Mostafa Omidian, Zohreh Mostafavi-Pour, Marzieh Asadi, Meysam Sharifdini, Navid Nezafat, Ali Pouryousef, Amir Savardashtaki, Mortaza Taheri-Anganeh, Fattaneh Mikaeili, Bahador Sarkari iD

PLOS Neglected Tropical Diseases · 15.07.2024 · 18 (7) · e0012320

DOI: 10.1371/journal.pntd.0012320 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 15.07.2024. Verfasst von Mostafa Omidian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Strongyloidiasis, Sensitivity and Specificity, Serologic Tests, Enzyme-Linked Immunosorbent Assay. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vice-Chancellor for Research of Shiraz University of Medical Sciences (SUMS to BS), Vice-Chancellor for Research, Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The sensitivity of parasitological and molecular methods is unsatisfactory for the diagnosis of strongyloidiasis, and serological techniques are remaining as the most effective diagnostic approach. The present study aimed to design and produce a chimeric recombinant antigen from Strongyloides stercoralis immunoreactive antigen ( SsIR ) and Ss1a antigens, using immune-informatics approaches, and evaluated its diagnostic performance in an ELISA system for the diagnosis of human strongyloidiasis. Methodology/Principal findings The coding sequences for SsIR and Ss1a were selected from GenBank and were gene-optimized. Using bioinformatics analysis, the regions with the highest antigenicity that did not overlap with other parasite antigens were selected. The chimeric recombinant antigen SsIR- Ss1a, was constructed. The solubility and physicochemical properties of the designed construct were analyzed and its tertiary structures were built and evaluated. The construct was expressed into the pET-23a (+) expression vector and the optimized DNA sequences of SsIR-Ss1a (873 bp) were cloned into competent E . coli DH5α cells. Diagnostic performances of the produced recombinant antigen, along with a commercial kit were evaluated in an indirect ELISA system, using a panel of sera from strongyloidiasis patients and controls. The physicochemical and bioinformatics evaluations revealed that the designed chimeric construct is soluble, has a molecular with of 35 KDa, and is antigenic. Western blotting confirmed the immunoreactivity of the produced chimeric recombinant antigen with the sera of strongyloidiasis patients. The sensitivity and specificity of the indirect ELISA system, using the produced SsIR-Ss1a chimeric antigen, were found to be 93.94% (95% CI, 0.803 to 0.989) and 97.22% (95% CI, 0.921 to 0.992) respectively. Conclusions/Significance The preliminary findings of this study suggest that the produced SsIR-Ss1a chimeric antigen shows promise in the diagnosis of human strongyloidiasis. However, these results are based on a limited panel of samples, and further research with a larger sample size is necessary to confirm its accuracy. The construct has potential as an antigen in the ELISA system for the serological diagnosis of this neglected parasitic infection, but additional validation is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

StrongyloidiasisSensitivity and SpecificitySerologic TestsEnzyme-Linked Immunosorbent AssayStrongyloides stercoralisAntigens, HelminthHumansAnimalsAntibodies, HelminthRecombinant Fusion ProteinsEscherichia coliRecombinant ProteinsGene Expression

Substanzen

Antigens, HelminthAntibodies, HelminthRecombinant Fusion ProteinsRecombinant Proteins

Autor:innen und Institutionen

  • Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Recombinant Proteins Laboratory, Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences Shiraz, Iran.
  • Department of Medical Parasitology and Mycology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

ORCID-Profile: Bahador Sarkari

Förderung

  • Vice-Chancellor for Research of Shiraz University of Medical Sciences (SUMS to BS)
  • Vice-Chancellor for Research, Shiraz University of Medical Sciences

Zitieren

APA

Omidian, M., Mostafavi-Pour, Z., Asadi, M., Sharifdini, M., Nezafat, N., Pouryousef, A., Savardashtaki, A., Taheri-Anganeh, M., Mikaeili, F., & Sarkari, B. (2024). Design and expression of a chimeric recombinant antigen (SsIR-Ss1a) for the serodiagnosis of human strongyloidiasis: Evaluation of performance, sensitivity, and specificity. PLOS Neglected Tropical Diseases, 18(7), e0012320. https://doi.org/10.1371/journal.pntd.0012320

Vancouver

Omidian M, Mostafavi-Pour Z, Asadi M, Sharifdini M, Nezafat N, Pouryousef A, et al. Design and expression of a chimeric recombinant antigen (SsIR-Ss1a) for the serodiagnosis of human strongyloidiasis: Evaluation of performance, sensitivity, and specificity. PLOS Neglected Tropical Diseases. 2024;18(7):e0012320. doi:10.1371/journal.pntd.0012320

BibTeX
@article{Omidian2024,
  author = {Omidian, Mostafa and Mostafavi-Pour, Zohreh and Asadi, Marzieh and Sharifdini, Meysam and Nezafat, Navid and Pouryousef, Ali and Savardashtaki, Amir and Taheri-Anganeh, Mortaza and Mikaeili, Fattaneh and Sarkari, Bahador},
  title = {Design and expression of a chimeric recombinant antigen (SsIR-Ss1a) for the serodiagnosis of human strongyloidiasis: Evaluation of performance, sensitivity, and specificity},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  volume = {18},
  number = {7},
  pages = {e0012320},
  doi = {10.1371/journal.pntd.0012320}
}
Kostenlos starten →